Author Interviews, JAMA, Mental Health Research, Pediatrics / 21.11.2017
Collaborative Effort Allows Oversight of Antipsychotic Medications in Medicaid Children
MedicalResearch.com Interview with:
Julie M. Zito, PhD
Professor of Pharmacy and Psychiatry
University of Maryland, Baltimore
Pharmaceutical Health Services Department
Baltimore, MD 21201
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: The growth of antipsychotic use in children, mainly for the treatment of behavior, has been of increasing concern in recent years. Clinical safety issues (Burcu et al. 2017) and government reports on overuse in the treatment of poor and foster care children (GAO, 2017; 2012) motivated our assessment of peer review programs. These programs are a relatively new approach to Medicaid oversight intended to monitor and assure clinical appropriateness of second generation antipsychotics in children. Critically important is the fact that most antipsychotic use is for child behavioral problems which are off-label conditions, i.e. without sufficient evidence of effectiveness or safety.
(more…)